Novel mechanisms of muscle and bone loss with HIV infection, antiretroviral therapy, and aging.

HIV 感染、抗逆转录病毒治疗和衰老导致肌肉和骨质流失的新机制。

基本信息

  • 批准号:
    10696502
  • 负责人:
  • 金额:
    $ 64.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-04-01 至 2028-03-31
  • 项目状态:
    未结题

项目摘要

Our proposal is in direct response to the special Funding Opportunity Announcement (FOA) PAR-21-068 “Multidisciplinary Studies of HIV/AIDS and Aging (R01)”. A frailty phenotype is frequently observed in HIV patients on long term antiretroviral therapy (ART), and both osteoporosis and sarcopenia are now recognized as co-morbidities among older people with HIV. Loss of muscle mass and strength are in turn associated with poor health outcomes ranging from falls and fractures to accelerated disease progression and increased mortality. Our goal is to address this problem by providing critical, new information on the cellular and molecular mechanisms underlying musculoskeletal dysfunction with HIV infection and ART, and thereby improve scientific knowledge, technical capability, and eventually clinical practice. Recent studies identify the aryl hydrocarbon receptor (AhR) as playing a key role in regulating organismal aging and lifespan. Our group has found that AhR activation can induce senescence in bone marrow stem cells, and others have observed that AhR overexpression induces muscle atrophy. Uniting these observations, our central hypothesis is that muscle- and bone-specific AhR activation are key drivers of muscle and bone loss in patients with HIV on ART. Our preliminary data provide a strong rationale for this hypothesis and indicate that 1) markers of muscle atrophy, bone loss, and AhR activation are increased in our mouse model of HIV infection, 2) AhR is highly expressed in muscle and bone, and targeted knockout of AhR in these tissues increases lean mass and trabecular bone mass, 3) pharmacological inhibition of AhR increases muscle strength and markers of bone formation in mice, and 4) the antiretroviral emtricitabine (FTC) increases AhR activation and senescence in muscle cells and these effects are attenuated by AhR silencing. Specific Aim 1 tests the hypothesis that AhR activation is a key factor driving muscle and bone loss with aging and HIV infection. Specific Aim 2 tests the hypothesis that AhR activation is a key factor driving muscle and bone loss with aging and antiretroviral therapy. Our expected outcomes include 1) defining the role of AhR in skeletal muscle and bone with HIV infection and ART so that it can be targeted therapeutically, and 2) characterizing the impact of aging and ART on AhR activation in skeletal muscle and bone. In the future this knowledge may be critical in the diagnosis, treatment and management of vulnerable patient populations debilitated by the vast array of HIV- and age-induced pathologies. Ultimately, these data will enable clinicians to improve disease outcomes and, consequently, public health.
我们的提案是对特别资助机会公告(FOA)PAR-21-068的直接回应 艾滋病毒/艾滋病和老龄化的多学科研究(R 01)。在HIV中经常观察到脆弱表型 长期接受抗逆转录病毒治疗(ART)的患者,骨质疏松症和肌肉减少症现在被认为是 老年艾滋病毒感染者的合并症。肌肉质量和力量的损失反过来又与穷人有关。 健康结果从福尔斯和骨折到加速疾病进展和增加死亡率。 我们的目标是通过提供关键的,新的细胞和分子信息来解决这个问题。 机制与HIV感染和ART的肌肉骨骼功能障碍,从而提高科学的 知识,技术能力,最终临床实践。最近的研究确定了芳烃 受体(AhR)在调节生物体衰老和寿命中起着关键作用。我们小组发现AhR 激活可以诱导骨髓干细胞衰老,其他人已经观察到AhR 过表达诱导肌肉萎缩。结合这些观察,我们的中心假设是,肌肉-和 骨特异性AhR激活是接受ART的HIV患者肌肉和骨丢失的关键驱动因素。 初步数据为该假设提供了强有力的理论基础并表明1)肌肉萎缩的标志物, 在我们的HIV感染小鼠模型中,骨丢失和AhR活化增加,2)AhR在 肌肉和骨骼,靶向敲除这些组织中的AhR增加了瘦体重和骨小梁质量, 3)AhR的药理学抑制增加小鼠的肌肉强度和骨形成的标志物,和4) 抗逆转录病毒恩曲他滨(FTC)增加了肌肉细胞中AhR的激活和衰老, 通过AhR沉默而减弱。具体目标1测试了AhR激活是驱动AhR的关键因素的假设 肌肉和骨质流失与衰老和艾滋病毒感染。具体目标2检验了AhR激活是一种 衰老和抗逆转录病毒治疗导致肌肉和骨质流失的关键因素。我们的预期成果包括:1) 明确AhR在HIV感染和ART的骨骼肌和骨骼中的作用, 2)表征衰老和ART对骨骼肌中AhR活化的影响, 骨头在未来,这些知识可能是诊断,治疗和管理脆弱的关键 患者群体因大量的艾滋病毒和年龄引起的病理而衰弱。最终,这些数据将 使临床医生能够改善疾病结果,从而改善公共卫生。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK W HAMRICK其他文献

MARK W HAMRICK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK W HAMRICK', 18)}}的其他基金

Effects of Myostatin Deficiency on Bone Strength
肌肉生长抑制素缺乏对骨强度的影响
  • 批准号:
    6929230
  • 财政年份:
    2004
  • 资助金额:
    $ 64.04万
  • 项目类别:
Effects of Myostatin Deficiency on Bone Strength
肌肉生长抑制素缺乏对骨强度的影响
  • 批准号:
    6827153
  • 财政年份:
    2004
  • 资助金额:
    $ 64.04万
  • 项目类别:
Effects of Myostatin Deficiency on Bone Strength
肌肉生长抑制素缺乏对骨强度的影响
  • 批准号:
    7084522
  • 财政年份:
    2004
  • 资助金额:
    $ 64.04万
  • 项目类别:
Effects of Myostatin Deficiency on Bone Strength
肌肉生长抑制素缺乏对骨强度的影响
  • 批准号:
    7228603
  • 财政年份:
    2004
  • 资助金额:
    $ 64.04万
  • 项目类别:
Regulation of Bone mass in Myostatin Deficient Mice
肌肉生长抑制素缺陷小鼠骨量的调节
  • 批准号:
    6314913
  • 财政年份:
    2001
  • 资助金额:
    $ 64.04万
  • 项目类别:
Core B - Bone Biology Core
核心 B - 骨生物学核心
  • 批准号:
    9902283
  • 财政年份:
  • 资助金额:
    $ 64.04万
  • 项目类别:
Project 2 - Role of bone-derived exosomes in musculoskeletal aging
项目 2 - 骨源性外泌体在肌肉骨骼衰老中的作用
  • 批准号:
    9902286
  • 财政年份:
  • 资助金额:
    $ 64.04万
  • 项目类别:
Core B - Bone Biology Core
核心 B - 骨生物学核心
  • 批准号:
    9209553
  • 财政年份:
  • 资助金额:
    $ 64.04万
  • 项目类别:
Project 2 - Role of bone-derived exosomes in musculoskeletal aging
项目 2 - 骨源性外泌体在肌肉骨骼衰老中的作用
  • 批准号:
    9209556
  • 财政年份:
  • 资助金额:
    $ 64.04万
  • 项目类别:
BONE BIOLOGY CORE
骨生物学核心
  • 批准号:
    8093265
  • 财政年份:
  • 资助金额:
    $ 64.04万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 64.04万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.04万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 64.04万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.04万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 64.04万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 64.04万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.04万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 64.04万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 64.04万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.04万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了